Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
in vivo CD20-targeting CAR-T (mRNA-LNP)
- Development stage
- Unknown
- Lead developer
- 1923rd Hospital of the Joint Logistics Support Force
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
This experimental in vivo CAR-T therapy, developed by The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, utilizes lipid nanoparticles (LNPs) to deliver mRNA encoding a CD20-specific chimeric antigen receptor (CAR) directly into the patient's body. Unlike traditional ex vivo CAR-T cell therapies, which require complex and time-consuming laboratory modification of a patient's T cells, this approach aims to reprogram T cells in situ. Once the mRNA is delivered and translated, the patient's own T cells transiently express the CAR, allowing them to identify and eliminate CD20-positive malignant B cells. This technology is being explored as a potentially more accessible, cost-effective, and rapid treatment for various B-cell hematological malignancies, including B-cell lymphoma and lymphocytic leukemia.
- Other names
- In vivo CAR-T drug targeting CD20 based on mRNA-LNPCD20-targeting mRNA-LNP CAR-TCD-20-targeting mRNA-LNP CAR-TCD 20-targeting mRNA-LNP CAR-Tin vivo CD20-targeting CAR-T
02
Targets
CD5 (T-cell surface glycoprotein CD5)CD3 (T-cell surface glycoprotein CD3)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on in vivo CD20-targeting CAR-T (mRNA-LNP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on in vivo CD20-targeting CAR-T (mRNA-LNP).